Interestingly, parallels exist between resistance mechanisms observed in TNBC and those described in hematologic malignancies such as myelodysplastic syndromes and acute myeloid leukemia, where reduced DCK activity and aberrant epigenetic regulator splicing contribute to DNMTi resistance [95,96]. The gene discussed is DCK; the disease is myelodysplastic syndrome.